TerminatedNot applicableNCT00212472
International Immune Tolerance Study
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New York Presbyterian Hospital
- Principal Investigator
- Donna M DiMichele, MDWeill Cornell Medical College-NY Presybetrian Hospital
- Intervention
- Factor VIII concentrates(drug)
- Enrollment
- 134 enrolled
- Eligibility
- 7 years · All sexes
- Timeline
- 2002 – 2012
Study locations (30)
- University of Alabama Birmingham Medical Center, Birmingham, Alabama, United States
- City of Hope Medical Center, Duarte, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Mountain States Regional Hemophilia and Thrombosis Center, Aurora, Colorado, United States
- All Children's Hospital, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Rush Presbyterian St. Lukes, Chicago, Illinois, United States
- Children's Memorial Hospital, Chicago, Illinois, United States
- Comprehensive Bleeding Disorders Center, Peoria, Illinois, United States
- Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana, United States
- Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
- Maine Children's Cancer Program, Scarborough, Maine, United States
- Tufts - New England Medical Center, Boston, Massachusetts, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- University of Michigan Health Hospitals, Ann Arbor, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Manchester University NHS Foundation Trust
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00212472 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07416604A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia AHoffmann-La Roche
- RECRUITINGPHASE3NCT07545395Safety of KN057 Prophylaxis in Patients With Haemophilia A or BSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06992076Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience RegistryInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France